Sinovac has four locations across China that house its R&D and manufacturing facilities. The Company is expanding its manufacturing capabilities to meet future demand for its pipeline vaccine products.
At its headquarters in Beijing, the Company has two production lines for the final bulk production of hepatitis vaccines and influenza vaccines. All of the existing two production lines are in compliance with China new GMP standard. The production line at its headquarters utilized to manufacture Healive and Bilive was designed by a European company using advanced equipment purchased from Europe and the United States.
At the facility located in the Changping district of Beijing that was acquired in February 2010, A new filling and packaging line in compliance with China new GMP standards has been bulit up and been fully operational since May of 2013. Sinovac has also built up a dedicated production linefor the production of EV71 vaccine under development. Currently, the construction has been completed and waits for the GMP certification and site inspection from CFDA according to the new drug application process of EV71 vaccine. Sinovac Dalian has one China new GMP certified production line in operation for the production of mumps vaccine. At both Changping and Sinovac Dalian, additional space is available for expansion to add more production lines as its pipeline products reach commercialization. At the Tangshan Yian location, Sinovac operates a R&D facility and is manufacturing its animal rabies vaccine.